^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Truxima (rituximab-abbs)

    i
    Other names: CT-P10, TL011, TL 011
    Company:
    Celltrion, Indukern, Mundipharma, Nippon Kayaku, Teva
    Drug class:
    CD20 inhibitor
    Related drugs:
    2d
    A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) (clinicaltrials.gov)
    P2/3, N=960, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD)
    7d
    ICP-CL-00128: A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-na?ve mantle cell lymphoma (2025-524241-27-00)
    P2/3, N=40, Not yet recruiting, Innocare Pharma Inc.
    New P2/3 trial
    |
    CCND1 (Cyclin D1)
    |
    Rituxan (rituximab) • Inokai (orelabrutinib) • bendamustine • Truxima (rituximab-abbs)
    14d
    M22-128: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2024-510965-41-00)
    P2/3, N=116, Active, not recruiting, AbbVie Deutschland GmbH & Co. KG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    gemcitabine • Rituxan (rituximab) • lenalidomide • oxaliplatin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs)
    24d
    ONO-4059-17: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) (2025-523389-26-00)
    P2/3, N=6, Not yet recruiting, Deciphera Pharmaceuticals Inc.
    New P2/3 trial
    |
    Rituxan (rituximab) • temozolomide • Truxima (rituximab-abbs) • Velexbru (tirabrutinib)
    27d
    Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs)
    28d
    Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=53, Terminated, M.D. Anderson Cancer Center | Trial completion date: Dec 2026 --> May 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2026 --> May 2026; <75% participation
    Trial completion date • Trial termination • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • nelarabine • Starasid (cytarabine ocfosfate)
    28d
    APHP240909: MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis interstitial lung disease (2025-521331-36-00)
    P2/3, N=120, Not yet recruiting, Assistance Publique Hopitaux De Paris
    New P2/3 trial
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs)
    28d
    Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • nemtabrutinib (MK-1026)
    1m
    Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=32, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Monjuvi (tafasitamab-cxix)
    1m
    Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=58, Not yet recruiting, City of Hope Medical Center
    New P1/2 trial
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)
    1m
    Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) (clinicaltrials.gov)
    P1/2, N=23, Not yet recruiting, University of Utah
    New P1/2 trial
    |
    Zynlonta (loncastuximab tesirine-lpyl) • Truxima (rituximab-abbs)
    1m
    NCI-2021-01791: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, OHSU Knight Cancer Institute | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    Venclexta (venetoclax) • dasatinib • Rituxan (rituximab) • Blincyto (blinatumomab) • methotrexate • Truxima (rituximab-abbs)